LXRX•benzinga•
Penny Stock Lexicon Pharmaceuticals Surges On Obesity Pact Worth $1 Billion With Novo Nordisk
Summary
Lexicon Pharmaceuticals granted Novo Nordisk exclusive rights to develop LX9851, an oral obesity drug, with potential milestone payments of up to $1 billion.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 28, 2025 by benzinga